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A 23-year-old woman with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like 
episodes) underwent a laparoscopy-assisted appendectomy.  MELAS syndrome is a multisystemic disease caused 
by mitochondrial dysfunction.  General anesthesia has several potential hazards to patients with MELAS syndrome, 
such as malignant hyperthermia, hypothermia, and metabolic acidosis. In this case, anesthesia was performed 
with propofol, remifentanil TCI, and atracurium without any surgical or anesthetic complications.  We discuss the 
anesthetic effects of MELAS syndrome.  (Korean J Anesthesiol 2010; 58: 409-412)
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    MELAS (mitochondrial myopathy, encephalopathy, lactic 
acidosis, and stroke-like episodes) syndrome is caused by a 
mitochondrial dysfunction that affects many organs; mutations 
in the genes in the mitochondrial DNA, which is inherited 
from the female parent, cause MELAS [1]. The mitochondrion 
produces ATP through the Krebs cycle and the electro-transfer 
system. It also plays a role in apoptosis-programmed cell 
death, cell division, steroid synthesis, regulation of cellular 
metabolism, and heat production in tissues. The mitochrondion 
is able to replicate and divide according to the cell’s energy 
needs. Diseases caused by mitochondrial dysfunctions, such as 
MELAS syndrome, have clinical manifestations predominantly 
in organs that require a lot of energy, such as brain, lungs, 
liver, and kidneys. Patients with the MELAS syndrome have 
reportedly experienced malignant hyperthermia, hypothermia, 
and resistance to muscle relaxants or their prolonged effects 
[2-6]. This case report describes the experiences with total 
intravenous anesthesia using target-controlled infusion of 
propofol and remifentanil to a MELAS syndrome patient 
undergoing a laparoscopic appendectomy.
Case Report
    A 23 year-old female patient, 160 cm tall and 48 kg, was 
diagnosed with acute appendicitis and admitted for a 
laparoscopic appendectomy. She had no abnormalities in her 410 www.ekja.org
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pediatric medical history, but from the age 18, she had slowly 
begun experiencing headaches in her left temporal lobe, 
nausea, and vomiting. In June of that year, she experienced 
generalized convulsions and aphasia. In a brain MRI and MRA, 
an infarction in the posterior divisions of the left mesencephalic 
arteries was found. Also, in a blood test, an increase in lactic 
acid was discovered (7.54 mM/L [normal level: 0.5-2.254 mM/
L]). The patient was suspected to have MELAS syndrome. She 
was diagnosed with MELAS after testing (adenosine-to-guanine 
transition at t-RNA nucleotide 3243 in PCR sequencing). After 
she turned 21, she was diagnosed with Type I DM. The patient 
had to orally ingest 200 mg of carbamazepine and 100 mg of 
aspirin per day and subcutaneously inject 30 units of insulin in 
the morning and 20 units in the evening. She had no history of 
total anesthesia. 
    In a physical examination before the anesthesia, the patient 
was able to read but had auditory aphasia such that she could 
not understand spoken words. In the physical examination, 
there were no signs of hypotonia or amyotrophy of the limbs. 
The laboratory results showed hyponatremia (126 mEq/L), 
hyperglycemia (257 mg/dl), and light metabolic acidosis (pH 
7.346, PaCO2 36.3 mmHg, HCO3 20.1 mM/L, BE -5.3 mM/
L). There were no abnormal findings in the chest X-ray and 
electrocardiogram. One year prior to her admission to the 
hospital, she had an ECG that revealed a cardiac index of 67% 
and no abnormal findings. For sugar control, 4 units of short-
acting insulin were injected, and 0.9% normal saline was 
administered to control hyponatremia. No other pre-operative 
measures were performed.
    After the patient was taken to the operating room, we attached 
ECG standard leads II, noninvasive monitors for blood pressure, 
heart rate, arterial oxygen saturation, capnogram, and bispectral 
index (BIS), and a nerve stimulator to the patient using the Multi 
Channel Anesthesia Monitor S/5
TM (Datex-Ohmeda, USA). 
Preliminary vital signs were as follows: blood pressure 115/65 
mmHg, heart rate 100 beats/min, oxygen saturation rate 97%, 
and the ECG results appeared normal. The patient underwent 
3 minutes of denitrogenation with 100% oxygen through a face 
mask. Afterwards, we administered lidocaine (40 mg) with the 
Master TCI (Fresenius Vial S.A., France); we then injected 2% 
propofol (Fresofol
Ⓡ, Fresenius Kabi, Austria) and remifentanil 
(Ultiva
TM, GlaxoSmithKline, UK) at target concentrations of 4 
μg/ml (Marsh-model) and 5 ng/ml (Minto-model), respecti-
vely. After roughly 90 seconds had passed, we checked lid 
reflexes and found that the patient had lost consciousness. 
We administered atracurium (0.5 mg/kg), the BIS was 50, and 
we saw that there was no response to TOF stimulation with 
the nerve stimulator placed on the ulnar nerve. Endotracheal 
intubation was then performed without complications. We 
started mechanical respiration with air (1.5 L/min), oxygen (1.5 
L/min), respiratory volume of 450 ml, and respiratory rate of 
12 breaths per minute. To control ventilation, the capnogram 
was kept at 35-40 mmHg. We used spirometry to measure 
the respiratory volume and pulmonary compliance. We started 
invasive blood pressure monitoring through the radial artery 
and measured the esophageal temperature with a body tempe-
rature monitor. During the operation, we used a forced-air 
warming blanket (Bair Hugger
TM, Austine Medical, USA) to 
stabilize the patient’s body temperature. For fluid maintenance, 
we administered 0.9% normal saline at 200 ml per hour. During 
the operation, the patient’s vitals were kept stable with blood 
pressure at 120-140/60-80 mmHg, heart rate 80-100 beats/
min, oxygen saturation 100%, body temperature 37.0-37.4
oC, 
and BIS 40-60. Thirty minutes after inducing anesthesia, the 
arterial blood gas study showed pH 7.44, PaCO2 32 mmHg, 
PaO2 299 mmHg, HCO3 23.3 mM/L, BE -2.1 mM/L; her elec-
trolytes were Na
+ 125 mEq/L, K
+ 3.8 mEq/L, Cl
- 88 mEq/
L; and her blood sugar was 176 mg/dl. Twenty minutes prior 
to the end of the operation, we administered ondansetron 
(4 mg) to prevent post-operative nausea and vomiting. After 
suturing the peritoneum, we stopped injecting remifentanil, 
kept the level of propofol in the target effect site at 2 μg/ml, 
and restored spontaneous breathing. After the operation was 
over, we stopped injecting propofol and stabilized spontaneous 
breathing at 300 ml per breath on the spirometer. On the nerve 
stimulator, the TOF rate was kept at 0.95. To reverse the muscle 
relaxant effects, we administered glycopyrrolate (0.4 mg) and 
pyridostigmine (15 mg). Afterwards, the patient responded 
to voice commands and opened her eyes. With stabilized 
spontaneous breathing, she was extubated. The operation lasted 
around 1 hour, and during the operation, 350 ml of 0.9% normal 
saline were used. We then moved the patient to the recovery 
room and kept her under observation with blood pressure, 
electrogram, and oxygen saturation monitors. In the recovery 
room, we gave her oxygen at 5 L/min through the facial mask. 
The arterial blood gas study showed pH 7.32, PaCO2 43 mmHg, 
PaO2 219 mmHg, HCO3 21.2 mM/L, and BE -3.6 mM/L; her 
electrolyte levels were Na
+ 128 mEq/L, K
+ 4.1 mEq/L, and Cl
-
90 mEq/L; and her blood sugar level was 120 mg/dl. We then 
moved the patient to the ward where we performed a lactic acid 
test, which measured 3.6 mM/L. Three days after the operation, 
the patient showed no complications from the operation or 
anesthesia, so she was released from the hospital. 
Discussion
    The mitochondrion synthesizes ATP from ADP and inorganic 
phosphate through the respiration chain. Thus, mitochondrial 
diseases can cause all kinds of organ dysfunctions. Clinical 
manifestations have been found in tissues with high levels of 411 www.ekja.org
Korean J Anesthesiol Park, et al.
energy consumption, such as brain and muscles. Kearns-Sayre 
syndrome, MELAS syndrome, mitochondrial myopathy, DAD 
(Diabetes mellitus and deafness), LHON (Leber’s hereditary 
optic neuropathy), Leigh syndrome, NARP (neuropathy, ataxia, 
retinitis pigmentosa, and ptosis), MERRF (myoclonic epilepsy 
with ragged red fibers) syndrome, and MNGIE (Myoneurogenic 
gastrointestinal encephalopathy) are all categorized as 
mitochondrial diseases.
    MELAS syndrome was first described by Pavlakis in 1984. 
It is characterized by dementia and seizures caused by 
encephalopathy, lactic acidosis, ragged-red fibers, and stroke-
like episodes that usually occur before the age of 40. There is 
also a build-up of lactic acid in plasma and cerebrospinal fluid. 
This mitochondrial disease is inherited from the female parent 
and is caused by an A-to-G transition mutation at position 3243 
of the mitochondrial genome. There is currently no curative 
treatment for the disease, but there have been various attempts 
of symptomatic treatment [1].
    Because MELAS syndrome causes systemic diseases that 
affect many organs, including the brain, a patient who needs 
to undergo general anesthesia will require careful anesthetic 
monitoring, especially of body temperature. Fricker et al. [2] 
reported a patient with mitochondrial myopathy accompanied 
by myoadenylate deaminase deficiency who was highly 
sensitive to his malignant hyperthermia. However, Morgan et 
al. [7] and Burns et al. [8] reported that there was no signifi  cant 
change in the patient’s body temperature when using sevoflurane 
and isoflurane for general anesthesia. There are controversies 
about the relationship between MELAS syndrome and malignant 
hyperthermia, but because MELAS syndrome is a mitochondrial 
disease, we must beware of malignant hyperthermia. Also during 
an operation, we must be careful of hypothermia because it 
can further inhibit mitochondrial functions [3]. In our case, 
we performed total intravenous anesthesia using propofol and 
remifentanil to prevent malignant hyperthermia; to prevent 
hypothermia, we continuously monitored body temperature 
via thermometer placed in the esophagus and used a forced-air 
warming blanket.
    When performing total intravenous anesthesia, propofol 
must be used with care. Propofol can cause mitochrondial 
dysfunction, which is thought to be caused by the propofol infu-
sion syndrome from extended use of propofol [9]. Cautionary 
use of propofol is therefore suggested in long operations. 
The present case was a short, 1-hour operation, so we did 
not experience any complications such as propofol-induced 
changes in heart functions or worsening of acidemia mid-
operation. 
    MELAS patients have varied experiences with non-depolarizing 
muscle relaxants. Finsterer et al. [4] and Wisely et al. [5] reported 
on mitochondrial myopathy patients who suffered prolonged 
effects from rocuronium and vecuronium. Aouad et al. [6] 
reported on MELAS patients with resistance to cisatracurium. 
Tempelhoff et al. [10] also reported patients resistant to non-
depolarizing muscle relaxants like the patient in our case; they 
stated that patients on anticonvulsants like carbamazepine 
and phenytoin experienced resistance. Because many MELAS 
patients also contract kidney disorders, for example, de Toni-
Debre-Fanconi syndrome, nephritic range proteinuria, and 
FSGS [1], causing a disorder in the excretion of drugs or 
extending the effects of the medicine, one should refrain from 
the usage of nephrotoxic drugs and drugs excreted by the 
kidneys. Thus, for our patient, we used atracurium, which is 
not excreted by the kidneys. We continuously checked the level 
of muscle relaxation and found neither prolonged effects nor 
resistance to the muscle relaxant.
    MELAS patients need to be carefully monitored for acidemia 
and electrolyte imbalance and require fluid therapy accordingly. 
Most patients have lactic acidosis and metabolic acidosis. 
Administering a fluid containing lactic acid, such as Ringer’s 
lactate solution, will worsen lactic acidosis, which will also cause 
metabolic acidosis. Because our patient had hyponatremia and 
lactic acidosis, we injected 0.9% normal saline. The patient’s 
hyponatremia was not corrected after the operation, but because 
she did not appear to have hyponatremia-caused reduced level 
of consciousness after regaining consciousness, it was not add-
ressed. 
    Problems in the cardiovascular system including cardiomyo-
pathy, WPW syndrome, and conduction disturbances are 
prevalent in MELAS patients [1]. Therefore, having an ECG prior 
to an operation is absolutely necessary, Echocardiography tests 
should be taken if possible, and continuous ECG monitoring 
and blood pressure monitoring are necessary during the 
operation and immediately thereafter. Moreover, the usage of 
drugs that cause changes in the cardiovascular system should 
be avoided or used carefully in small amounts during the 
operation.
    Diabetes is the most prevalent disease in MELAS patients [1]. 
When the patient has to fast for the surgery, the tissue cells 
cannot get enough energy for fast metabolism, and build-up 
of metabolites such as lactic acid worsens the lactic acidosis. 
Therefore, before and after surgery, the patient’s blood sugar 
level must be carefully controlled with particular caution so 
that the patient does not experience hypoglycemia during 
anesthesia. In the present case, we administered short-acting 
insulin to the patient for hyperglycemia. Also, before, during, 
and after anesthesia in the recovery room, we regularly 
monitored her blood sugar level, but the patient did not have 
significant hypoglycemia or hyperglycemia.
    In conclusion, because MELAS syndrome affects all organs, 
particularly in the excretory system, cardiovascular system, 412 www.ekja.org
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and respiratory system, general anesthesia for MELAS patients 
requires special attention to the choices of the anesthetic method, 
drugs, and fluid. Therefore, in pre-anesthetic evalu  ations, one 
must take all symptoms of the body into consideration and 
carefully monitor the patient for various complications, such as 
malignant hyperthermia, hypothermia, prolongation of muscle 
relaxant effects, and instability in the cardiovascular system, 
during the operation.
References
1. Sproule DM, Kaufmann P. Mitochondrial encephalopathy, lactic 
acidosis, and strokelike episodes. basic concepts, clinical phenotype, 
and therapeutic management of MELAS syndrome. Ann NY Acad 
Sci 2008; 1142: 133-58.
2. Fricker RM, Raffelsberger T, Rauch-Shorny S, Finsterer J, Müller-
Reible C, Gilly H, et al. Positive malignant hyperthermia suscep-
tibility in vitro test in a patient with mitochondrial myopathy and 
myoadenylate deaminase deficiency. Anesthesiology 2002; 97: 
1635-7.
3. Cholley F, Edery P, Ricquier D, Peudenier S, Slama A, Tardieu M. 
Mitochondrial respiratory chain deficiency revealed by hypother-
mia. Neuropediatrics 2001; 32: 104-6.
4. Finsterer J, Stratil U, Bittner R, Sporn P. Increased sensitivity to 
rocuronium in mitochondrial myopathy. Can J Anaesth 1998; 45: 
781-4.
5. Wisely NA, Cook PR. General anesthesia in a man with mitochon-
drial myopathy undergoing eye surgery. Eur J Anaesthesiol 2001; 
18: 333-5.
6. Aouad MT, Gerges FJ, Bararka AS. Resistance to cisatracurium in a 
patient with MELAS syndrome. Paediatr Anaesth 2005; 15: 1124-7.
7. Morgan PG, Hoppel CL, Sedensky MM. Mitochondrial defects and 
anesthetic sensitivity. Anesthesiology 2002; 96: 1268-70.
8. Burns AM, Shelly MP. Anaesthesia for patients with mitochondrial 
myopathy. Anaesthesia 1989; 44: 975-7.
9. Vasile B, Rasulo F, Candiani A, Latronico N. The pathophysiology 
of propofol infusion syndrome: a simple name for a complex 
syndrome. Intensive Care Med 2003; 29: 1417-25.
10. Tempelhoff R, Modica PA, Jellish WS, Spitznagel EL. Resistance 
to atracurium-induced neuromuscular blockade in patients with 
intractable seizure disorders treated with anticonvulsants. Anesth 
Analg 1990; 71: 665-9.